Research lines

PDE7 inhibitors

With the aim to develop new therapeutic approaches for the treatment of neurodegenerative diseases, the validation of phosphodiesterase 7 (PDE7) as therapeutic target for the treatment of inflammatory and immunological disorders is carried out.

This research line is based on the design and synthesis of selective and chemical diverse PDE7 inhibitors. The effects of PDE7 inhibition on neuroprotection and neuroinflammation, together with their efficacy on animal models for multiple sclerosis such as EAE or Theiler virus, for Parkinson disease such LPS-ecitotoxicity and/or on stroke models of cerebral ischemia are being also studied.


Guadalupe Mengod, PhD. Instituto de Investigaciones Biomédicas de Barcelona-CSIC. Barcelona (Spain)

Ana Pérez-Castillo, PhD, Instituto de Investigaciones Biomédicas "Alberto Sols"-CSIC. Madrid (Spain)

Carmen Guaza, PhD, Instituto de Neurobiologia Ramón y Cajal-CSIC. Madrid (Spain)

María Ángeles Moro, PhD, Facultad de Medicina Universidad Complutense, Madrid (Spain)

Sara Ballester, PhD. Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid (Spain)

Francisco Javier Luque, PhD. Facultad de Farmacia, Universidad de Barcelona (Spain)

Hengming Ke, PhD. University of North Carolina at Chapel Hill, (USA)

Stefan Bräse, PhD. Karlsruhe University (Germany)